original ) (raw )Correlation of mycophenolic acid pharmacokinetic parameters with side effects in Chinese kidney transplant recipients treated with mycophenolate mofetil
Raf Schepers
Transplantation Proceedings, 2004
View PDFchevron_right
Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant
M. Durlik
Journal of Clinical Pharmacy and Therapeutics, 2006
View PDFchevron_right
Drug Tolerability and Outcomes in Kidney Transplant Recipients Treated with Two Formulations of Mycophenolic Acid
Rod Mateo
Journal of Pharmaceutics and Drug Development, 2013
View PDFchevron_right
Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients
Magdalena Korecka
Clinical Biochemistry, 2001
View PDFchevron_right
Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings
David Roth
Transplant Immunology, 1997
View PDFchevron_right
Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil
Marc L. Melcher
British Journal of Clinical Pharmacology, 2003
View PDFchevron_right
Mycophenolic Acid Pharmacokinetics Early After Kidney Transplant
kheirollah Gholami
Experimental and Clinical Transplantation, 2013
View PDFchevron_right
Mycophenolic Acid 12-h Trough Level Monitoring in Renal Transplantation: Association with Acute Rejection and Toxicity
Megan Griffith
American Journal of Transplantation, 2006
View PDFchevron_right
Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients
Petra Reinke
Transplant International, 2012
View PDFchevron_right
Limited Sampling Strategy of Mycophenolic Acid in Adult Kidney Transplant Recipients: Influence of the Post‐Transplant Period and the Pharmacokinetic Profile
Nadia Ben Fredj
The Journal of Clinical Pharmacology, 2013
View PDFchevron_right
Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients
Monica Cortinovis
Clinical Journal of the American Society of Nephrology, 2007
View PDFchevron_right
Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study
Willem Weimar
Nephrology Dialysis Transplantation, 1999
View PDFchevron_right
Pharmacodynamic evaluation of the first dose of mycophenolate mofetil before kidney transplantation
Petra Glander
Clinical Journal of the …, 2009
View PDFchevron_right
Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics
Lutz Renders
Clinical pharmacology and therapeutics, 2009
View PDFchevron_right
Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation
Eberhard Wieland , Catherine M T Sherwin , Alexander Vinks
Clinical Transplantation, 2012
View PDFchevron_right
The Rationale for and Limitations of Therapeutic Drug Monitoring for Mycophenolate Mofetil in Transplantation
Leslie Shaw
Transplantation, 2005
View PDFchevron_right
The use of mycophenolate mofetil in liver transplant recipients
Jean Delwaide
Expert Opinion on Pharmacotherapy, 2003
View PDFchevron_right
A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil
Yvon Lebranchu , Jean Debord
Clinical Pharmacokinetics, 2005
View PDFchevron_right
Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients
Fawzy Elbarbry
Clinical Biochemistry, 2007
View PDFchevron_right
Therapeutic Monitoring of Mycophenolate Mofetil in Organ Transplant Recipients
Pierre Wallemacq
Clinical Pharmacokinetics, 2002
View PDFchevron_right
Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients
Anders Hartmann
Transplant International, 2006
View PDFchevron_right
The CLEAR Study: A 5-day, 3-g Loading Dose of Mycophenolate MofetilversusStandard 2-g Dosing in Renal Transplantation
Ahmed Shoker
Clinical Journal of the American Society of Nephrology, 2010
View PDFchevron_right
Time-dependent clearance of mycophenolic acid in renal transplant recipients
Teun Van Gelder
British Journal of Clinical Pharmacology, 2007
View PDFchevron_right
Evaluation of Limited Sampling Strategies for Mycophenolic Acid After Mycophenolate Mofetil Intake in Adult Kidney Transplant Recipients
Christine Staatz
2010
View PDFchevron_right
Unexpected augmentation of mycophenolic acid pharmacokinetics in renal …
David Roth
Transplant …, 1997
View PDFchevron_right
Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus
Anis Klouz
Clinical …, 2002
View PDFchevron_right
The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy
Domingo Hernández
Nephrology Dialysis Transplantation, 2009
View PDFchevron_right
Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients
Petra Glander
Clinical Journal of The American Society of Nephrology, 2010
View PDFchevron_right
Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation
Rory Remmel
Clinical pharmacology and therapeutics, 2005
View PDFchevron_right
Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation
Mahmud Mourad
Clinical …, 2001
View PDFchevron_right